glibenclamide

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Multiple SclerosisOxidative StressIntracerebral HemorrhageHyperglycaemia

145 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

1

Cytoxan

BBaxter Healthcare Corporation

Phase 3

92

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

23

Zyrtec

KKenvue Brands

Phase 3

14

Activated Charcoal

Sanofi

Phase 3

15

Mayzent

Novartis

Phase 3

16

Antihistamine

Arrowhead Pharmaceuticals

Phase 3

27

Recombinant Zoster Vaccine

MMAXVAX Biotechnology Limited Liability Company

Phase 3

18

MRI Contrast-Enhancing Agents

Sanofi

Phase 3

39

Tolebrutinib

Sanofi

Phase 3

410

glibenclamide

Novo Nordisk

Phase 2

1Show 25 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Type 2 Diabetes6 trials

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Completed·Novo Nordisk·Phase 3·NCT00393718·400 enrolled

Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes

Terminated·Novo Nordisk·Phase 3·NCT00267683·9 enrolled

Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension

Completed·—·Phase 4·NCT02145611·50 enrolled

Show 3 more trials

Risk of Hypoglycemia in Type 2 Diabetes

Completed·UUniversity of Giessen··NCT00734669·12 enrolled

Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes

Completed·AAzienda Ospedaliero-Universitaria di Parma·Phase 3·NCT01822548·64 enrolled

Evaluation of Cissus Verticillata L. Infusion in Controlling Type 2 Diabetes

Completed·FFederal University of Paraíba·Phase 1/2·NCT01145534·15 enrolled

Diabetes2 trials

Low dosE GlibENclamide in Diabetes Part A

Completed·UUniversity of Oxford·Phase 2·NCT02830048·16 enrolled

Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02375828·10 enrolled

Hemodynamic2 trials

The Hemodynamic Effects of CGRP After Glibenclamide Administration in Healthy Volunteers

Completed·DDanish Headache Center·N/A·NCT04231617·20 enrolled

The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers

Completed·DDanish Headache Center·N/A·NCT04960657·22 enrolled

LAM1 trial

GALLANT 4 Tesaglitazar vs. Glibenclamide

Terminated·AstraZeneca·Phase 3·NCT00255541·580 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism

Completed·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03284463·306 enrolled

18 more indications

GLP-11 trial

Cardioprotective Effects of GLP-1 and Their Mechanisms

Completed·PPapworth Hospital NHS Foundation Trust·Phase 1·NCT02128022·32 enrolled

ESS1 trial

Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study

Completed·KKhoo Teck Puat Hospital·Phase 4·NCT02201602·8 enrolled

Oxidative Stress1 trial

The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation

Unknown status·—·N/A·NCT00696982·60 enrolled

Acute1 trial

Evaluate the Use of Glibenclamide on Acute aSAH

Unknown status·—·Phase 4·NCT05137678·110 enrolled

Function1 trial

Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?

Unknown status·KKing's College Hospital NHS Trust·Phase 4·NCT00472875·10 enrolled

Diabetes Mellitus1 trial

Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT00610038·19 enrolled

Brain Edema1 trial

To Evaluate the Effect of Glibenclamide in Reducing Brain Edema of TBI

Unknown status·—·Phase 1/2·NCT05148403·76 enrolled

Type 2 Diabetes Mellitus1 trial

Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)

Completed·Merck & Co.·Phase 4·NCT02318693·53 enrolled

Gestational Diabetes1 trial

A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS

Completed·UUniversity of Edinburgh·Phase 3·NCT02080377·23 enrolled

Injury1 trial

Ischemic Injury and Ischemic Preconditioning in Diabetes

Completed·RRadboud University Medical Center··NCT00184821·20 enrolled

Multiple Sclerosis1 trial

OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis

Not yet recruiting·UUniversity of Maryland, Baltimore·Phase 1·NCT07221799·10 enrolled

Endothelial Dysfunction1 trial

Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery

Completed·UUniversity of Campinas, Brazil·Phase 4·NCT02919345·98 enrolled

Hypertensive1 trial

Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects

Completed·UUniversity of Campinas, Brazil·Phase 4·NCT03089333·16 enrolled

Intracerebral Hemorrhage1 trial

Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage

Completed·XXijing Hospital·N/A·NCT03741530·220 enrolled

Metformin1 trial

A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects

Completed·CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04859452·56 enrolled

Subarachnoid Hemorrhage1 trial

Glibenclamide in Aneurysmatic Subarachnoid Hemorrhage

Unknown status·UUniversity of Sao Paulo General Hospital·Phase 4·NCT03569540·50 enrolled

Hyperglycaemia1 trial

Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05687500·35 enrolled

Hypoglycemia1 trial

Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DM

Completed·UUniversity Hospital, Basel, Switzerland·Phase 2/3·NCT00515801·18 enrolled

Details

Drug Info

Related News